Paracetamol / Ibuprofen for Postpartum Pain in the Early Postpartum Period
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04653506 |
Recruitment Status :
Recruiting
First Posted : December 4, 2020
Last Update Posted : December 14, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pain | Drug: Paracetamol 1000 mg Drug: Ibuprofen 400 mg | Not Applicable |
Postpartum pain is a common problem that leads to difficulties in basic daily activities, overuse of opioid medications, and even impaired breastfeeding ability. Non-opioid analgesia may play an essential role in reducing pain and improving the postpartum period including the ability to breastfeed and caring for the newborn.
This study will compare non-opioid treatment - 1000 mg Paracetamol versus 400 mg Ibuprofen in order to determine the optimal pain relief treatment in the early postpartum period that may decrease the use of opioid analgesia.
The investigators will evaluate the pain by the Numerical Rating Scale (NRS) index in the early postpartum period. The evaluation will conduct at 4-time points - while the women taking the pain relief (time 0), an hour later (time 1), 4, and 6 hours later (time 4 and time 6).
The investigators will compare the analgetic effect of each drug and evaluate the need for additional analgesia whether opioid or not.
Furthermore, the investigators will examine when women sought pain relief and whether pain relief contributes to the ability of Breastfeeding.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 1000 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: |
|
Masking: | Double (Participant, Care Provider) |
Masking Description: | The primary investigator will be the only one to have the information about envelopes contain |
Primary Purpose: | Treatment |
Official Title: | Non - Opioid Treatments (Single Administration) for Pain During the Early Postpartum Period After Vaginal Delivery |
Actual Study Start Date : | November 28, 2020 |
Estimated Primary Completion Date : | November 28, 2022 |
Estimated Study Completion Date : | November 28, 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: Paracetamol group
Women who were treated with a double-blind mechanism in an envelope containing paracetamol pills (1000 mg)
|
Drug: Paracetamol 1000 mg
Women participating in the study will receive postpartum analgesia immediately while reporting pain requiring analgesia, by envelope contains paracetamol 1000 mg or ibuprofen 400 mg |
Experimental: Ibuprofen group
Women who were treated with a double-blind mechanism in an envelope containing Ibuprofen pills (400 mg)
|
Drug: Ibuprofen 400 mg
Women participating in the study will receive postpartum analgesia immediately while reporting pain requiring analgesia, by envelope contains paracetamol 1000 mg or ibuprofen 400 mg |
- Pain relief after treatment with Paracetamol or Ibuprofen [ Time Frame: 6 hours after intervention ]After getting a pain relief treatment, the participants will answer a questionnaire about pain relief at 4 - time points: the time of getting the pain relief treatment (time 0), after an hour (time 1), 4 hours (time 4), and six hours (time 6). The pain rating will be on the Numeric Rating Scale (NRS) that labeled from zero (no pain) to ten ((worst pain).
- Maximum pain location [ Time Frame: 6 hours after intervention ]After getting a pain relief treatment, the participants will answer a questionnaire about pain relief at 4 - time points: the time of getting the pain relief treatment (time 0), after an hour (time 1), 4 hours (time 4), and six hours (time 6). The questionnaire will describe the maximal pain location area and the effectiveness of analgesic treatment in this area (by rating the pain on the NRS). The questionnaire will be at the time of taking the pain relief treatment (time 0), after an hour (time 1), 4 hours (time 4), and six hours (time 6)
- Effect on breastfeeding [ Time Frame: 6 hours after intervention ]The participants will answer a questionnaire that will describe the effect of' pain relief on a woman's ability to breastfeed. The questionnaire will ask their desire to breastfeed before giving birth, did they really manage to breastfeed, and when they started breastfeeding. The investigator will describe if there is a correlation between pain relief and the ability to breastfeed.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 50 Years (Adult) |
Sexes Eligible for Study: | Female |
Gender Based Eligibility: | Yes |
Gender Eligibility Description: | Postpartum women |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Women between the ages of 18-50, who gave birth in a vaginal birth
Exclusion Criteria:
- Sensitivity to Paracetamol or Ibuprofen
- After cesarean section
- Received analgesia prior to study recruitment
- Perineal tears grade 3 \ 4
- Women with chronic pain, rheumatic disease, fibromyalgia, or trauma
- Women with a diagnosis or medication for anxiety or depression
- Dropout for women whose newborns needed respiratory support with intubation, cooling, prolonged hospitalization in NICU exceeding one week

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04653506
Contact: Shai Ram, MD | 972 0506337159 | shairam85@gmail.com | |
Contact: Sharon Maslovitz, MD | 972527360048 | MASLOVITZ@gmail.com |
Israel | |
Tel Aviv Medical Center | Recruiting |
Tel Aviv, Israel, 6423906 | |
Contact: shai ram, MD +972506337159 shairam85@gmail.com | |
Contact: MD | |
Principal Investigator: Sharon Maslovitz, MD | |
Principal Investigator: Shai Ram, MD |
Principal Investigator: | shai ram, MD | Tel Aviv Medical Center |
Responsible Party: | Eli Sprecher, MD, director head of clinical trails department, principal investigator, clinical professor, Tel-Aviv Sourasky Medical Center |
ClinicalTrials.gov Identifier: | NCT04653506 |
Other Study ID Numbers: |
0368-20-TLV |
First Posted: | December 4, 2020 Key Record Dates |
Last Update Posted: | December 14, 2020 |
Last Verified: | December 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Post Partum Pain, Pain Relief, Non-Opioids Analgesia |
Acetaminophen Ibuprofen Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents |
Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents Cyclooxygenase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antipyretics |